Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Cheuk-Man Yu,
Prof. Kenneth Dickstein,
Presenter | see Discussant report
Cheuk-Man Yu (Hong Kong SAR, People's Republic of China)Presentation webcastPresentation slides
List of Authors: Cheuk-Man Yu, MD, FRCP; Fang Fang, PhD, Jeffrey Wing-Hong Fung, MD, FRCP Qing Zhang, MM, PhD; Omar Razali, MD; Gabriel Wai-Kwok Yip, MD, FACC; Hussin Azlan, MD; Hamish Chi-Kin Chan, FRCP; Joseph Yat-Sun Chan, FHKAM(Medicine)
Objectives: Pacing to Avoid Cardiac Enlargement (PACE) trial is a prospective, double-blinded, randomized, multicenter study that reported the superiority of biventricular (BiV) pacing to right ventricular apical (RVA) pacing in prevention of left ventricular (LV) adverse remodeling and deterioration of systolic function at 1-year. In the current analysis, we reported the results at extended 2-year follow-up and the potential baseline predictors of deterioration of LV systolic function. Methods: Patients (N=177) with bradycardia and preserved LV ejection fraction (EF) were randomized to receive RVA or BiV pacing. Co-primary end-points were LV end-systolic volume (LVESV) and LVEF measured mostly be 3D echocardiography. Primary analysis was based on intention-to-treat, and drop outs were analyzed according to last-observation-carried-forward principle. Results: Eighty-one (92%) out of 88 patients in RVA pacing group and 82 (92%) out of 89 patients in BiV pacing group completed 2-year follow-up. In the RVA pacing group, LVEF further decreased from 1st to 2nd year, but remain unchanged in the BiV pacing group, leading to a significant difference of 9.9 points at 2nd year (p<0.001) (Table). Similarly, LVESV continue to enlarge from 1st to 2nd year in the RVA pacing group, leading to a difference of 13.0ml (p<0.001). There were 4 deaths in the RVA group and 3 in BiV group (log-rank χ2=0.15, p=0.62); and 6 hospitalization in RVA pacing group 5 in BiV pacing group for heart failure (Log rank χ2=0.17, p=0.68). Eighteen patients in BiV pacing group (20.2%) and 55 in RVA pacing group (63.0%) had significant reduction of LVEF, ie.≥5% (2=32.6, p<0.001). Conclusion: LV adverse remodeling and deterioration of systolic function continues at the 2nd year after RVA pacing, which was prevented effectively by the use of BiV pacing.
Discussant | see Presenter abstract
Kenneth Dickstein (Norway)Presentation webcastPresentation slides
(European Heart Journal, ESC Clinical trial update complimentary, doi:10.1093/eurheartj/ehr337) This editorial refers to ‘Biventricular pacing is superior to right ventricular pacing in bradycardia patients with preserved systolic function: 2-year results of the PACE trial,’ by J.Y.-S Chan et al., doi:10.1093/eurheartj/ehr336. In medicine, it is encouraging when research yields results consistent with our understanding of the operative mechanisms, especially when there is a direct potential impact on clinical practice. Chan et al. have provided us with such a result and a clear message.1 The 2-year follow-up in the Pacing to Avoid Cardiac Enlargement (PACE) trial confirms that chronic right ventricular (RV) pacing in patients with bradycardia and preserved left ventricular (LV) function leads to sustained and progressive deterioration of LV ejection fraction (EF) and increases in LV volumes. This adverse remodelling process was prevented by pacing with cardiac resynchronization therapy (CRT). Adverse LV remodelling is a complex maladaptive process involving... [more in EHJ: doi:10.1093/eurheartj/ehr337].
710003 - 710004
Clinical Trial Update II - Rate and rhythm